Hemispherx forms data-monitoring team

A three-member independent data-monitoring committee will now oversee drug development, provide interim analyses of outcomes data, and ensure subject safety for Hemispherx Biopharma. The committee also will play a role in adaptive trials, overseeing such trial design modifications as eliminating a treatment arm or modifying sample size to increase the statistical probability of success. The committee formation follows last year's no vote by the FDA on Ampligen, an experimental treatment for chronic fatigue syndrome. Release | Article

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.